Subscribe To
Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting

Clinical dose escalation data for RMC-6236, a RASMULTI(ON) Inhibitor, show oral bioavailability, well-tolerated safety profile and preliminary evidence of anti-tumor activity across multiple RAS mutations First clinical data presentation for RMC-6291, a RASG12C(ON) Inhibitor, highlights encouraging initial tolerability, safety and differentiated anti-tumor activity Investor webcast to be held Sunday, October 22 at 12:30pm Eastern Time […] The post Revolution Medicines Presents Encouraging Clini...
Read More
Posted: Oct 13 2023, 15:50
Author Name: forextv
Views: 082562